The Procalcitonin And Survival Study (PASS)
Author Information
Author(s): Jens-Ulrik Jensen, Bettina Lundgren, Lars Hein, Thomas T Mohr, Pernille L Petersen, Lasse H Andersen, Anne Ø Lauritsen, Sine Hougaard, Teit Mantoni, Bonnie Bømler, Klaus J Thornberg, Hamid Tousi, Kim M Larsen, Paul Fjeldborg, Carsten B Thomsen, Peter Søe-Jensen, Jesper Løken, Mads H Andersen, Charlotte D Rossau
Primary Institution: Hvidovre Hospital
Hypothesis
Daily measurements of the infection biomarker Procalcitonin can precisely and in a timely manner monitor the emergence and the course of a serious infection in ICU patients and can via rapid and sufficient changes in the diagnostics and therapeutics increase the survival rate.
Conclusion
The study aims to determine if using Procalcitonin levels to guide treatment can improve survival rates in critically ill patients.
Supporting Evidence
- Procalcitonin is a sensitive and specific biomarker for bacterial sepsis.
- The level of Procalcitonin increases rapidly after infection, providing timely information for treatment.
- Previous studies have shown a correlation between Procalcitonin levels and infection severity.
Takeaway
This study is trying to see if checking a special blood marker every day can help doctors treat very sick patients better and save more lives.
Methodology
Multi-centre randomized controlled trial with two arms: one receiving standard care and the other receiving Procalcitonin-guided treatment.
Potential Biases
Potential bias in patient selection and treatment adherence.
Limitations
The study may not account for all variables affecting patient outcomes, and results may not be generalizable to all ICU settings.
Participant Demographics
Patients aged 18 and older admitted to intensive care units.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website